Protara Therapeutics, Inc. (TARA) on Friday announced positive updated 12-month data from the Phase 2 ADVANCED-2 study evaluating TARA-002 in certain patients with non-muscle invasive bladder cancer (NMIBC).
The study is evaluating intravesical TARA-002 in patients with carcinoma in situ who are Bacillus Calmette-Guérin (BCG)-unresponsive or BCG-naïve.
Results from Cohort A showed a complete response rate of 72.4% in BCG-naïve patients at any time during the study. The complete response rate was 66.7% at six months and 55.0% at 12 months.
Among responders, the Kaplan-Meier estimated probability of maintaining a complete response for six months was 73.1%, while 91.7% of patients maintained their complete response from nine to 12 months.
The company said most treatment-related adverse events were Grade 1 and transient, with no Grade 3 or higher treatment-related adverse events reported.
Protara added that it remains on track to initiate the ADVANCED-3 registrational trial in BCG-naïve patients in the second half of 2026.
The company's shares were down more than 1% in pre-market trading after closing at $5.30 on Thursday.
For comments and feedback contact: editorial@rttnews.com
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.